Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1, 3,4-oxadiazoline analogs of combretastatin-A4

Journal of Medicinal Chemistry

Volumn 53, Issue 1, 2010, Pages 325-334

  Lee, Lauren ^a   Robb, Lyda M ^b   Lee, Megan ^a   Davis, Ryan ^a   Mackay, Hilary ^a   Chavda, Sameer ^a   Babu, Balaji ^a   O'Brien, Erin L ^b   Risinger, April L ^b   Mooberry, Susan L ^b   Lee, Moses ^a  

^a HOPE COLLEGE   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2',5' DIMETHOXYPHENYL) 5 (3'' METHOXYPHENYL) 2 ACETYL 2,3 DIHYDRO 1,3,4 OXADIAZOLINE; 2 (3' BROMOPHENYL) 5 (3'',4'',5'' TRIMETHOXYPHENYL) 2 ACETYL 2,3 DIHYDRO 1,3,4 OXADIAZOLINE; 2 (3',4',5' TRIMETHOXYPHENYL) 5 (3'' METHOXYPHENYL) 2 ACETYL 2,3 DIHYDRO 1,3,4 OXADIAZOLINE; 2 (3',5' DIMETHOXYPHENYL) 5 (3'' METHOXYPHENYL) 2 ACETYL 2,3 DIHYDRO 1,3,4 OXADIAZOLINE; COMBRETASTATIN A4; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; MICE; MOLECULAR STRUCTURE; OXADIAZOLES; STEREOISOMERISM; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74849140125     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901268n     Document Type: Article

References (35)

1. Pettit, G. R.; Singh, S. B.; Niven, M. L.; Hamel, E.; Schmidt, J. M. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J. Nat. Prod. 1987, 50, 119-131.
2. Pettit, G. R.; Cragg, G. M.; Singh, S. B. Antineoplastic agents, 122. Constituents of Combretum caffrum. J. Nat. Prod. 1987, 50, 386-391.
3. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989, 45, 209-211.
4. Lin, C. M.; Singh, S. B.; Chu, P. S.; Dempcy, R. O.; Schmidt, J. M.; Pettit, G. R.; Hamel, E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol. 1988, 34, 200-208.
5. Dorr, R. T.; Dvorakova, K.; Snead, K.; Alberts, D. S.; Salmon, S. E.; Pettit, G. R. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest. New Drugs 1996, 14, 131-137.
6. Dark, G. G.; Hill, S. A.; Prise, V. E.; Tozer, G. M.; Pettit, G. R.; Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997, 57, 1829-1834.
7. Tozer, G. M.; Prise, V. E.; Wilson, J.; Locke, R. J.; Vojnovic, B.; Stratford,M. R.; Dennis,M. F.; Chaplin, D. J. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res. 1999, 59, 1626-1634.
8. Galbraith, S. M.; Maxwell, R. J.; Lodge, M. A.; Tozer, G. M.; Wilson, J.; Taylor, N. J.; Stirling, J. J.; Sena, L.; Padhani, A. R.; Rustin, G. J. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 2003, 21, 2831-2842.
9. Stevenson, J. P.; Rosen, M.; Sun, W.; Gallagher, M.; Haller, D. G.; Vaughn, D.; Giantonio, B.; Zimmer, R.; Petros, W. P.; Stratford, M.; Chaplin, D.; Young, S. L.; Schnall, M.; O′Dwyer, P. J. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 2003, 21, 4428-4438.
10. Chaplin, D. J.; Horsman, M. R.; Siemann, D. W. Current development status of small-molecule vascular disrupting agents. Curr. Opin. Invest. Drugs 2006, 7, 522-528.
11. Kanthou, C.; Tozer, G. M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002, 99, 2060-2069.
12. Vincent, L.; Kermani, P.; Young, L. M.; Cheng, J.; Zhang, F.; Shido, K.; Lam, G.; Bompais-Vincent, H.; Zhu, Z.; Hicklin, D. J.; Bohlen, P.; Chaplin, D. J.; May, C.; Rafii, S. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J. Clin. Invest. 2005, 115, 2992-3006.
13. Samarin, J.; Rehm, M.; Krueger, B.; Waschke, J.; Goppelt-Struebe, M. Up-regulation of connective tissue growth factor in endothelial cells by the microtubule-destabilizing agent combretastatin A-4. Mol. Cancer Res. 2009, 7, 180-188.
14. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: Present and future directions. J. Med. Chem. 2006, 49, 3033-3044.
15. Hinnen, P.; Eskens, F. A. Vascular disrupting agents in clinical development. Br. J. Cancer 2007, 96, 1159-1165.
16. LeBlanc, R.; Dickson, J.; Brown, T.; Stewart, M.; Pati, H. N.; VanDerveer, D.; Arman, H.; Harris, J.; Pennington, W.; Holt, H. L., Jr.; Lee, M. Synthesis and cytotoxicity of epoxide and pyrazole analogs of the combretastatins. Bioorg. Med. Chem. 2005, 13, 6025-6034.
17. Johnson, M.; Younglove, B.; Lee, L.; Leblanc, R.; Holt, H., Jr.; Hills, P.; Mackay, H.; Brown, T.; Mooberry, S. L.; Lee, M. Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4. Bioorg. Med. Chem. Lett. 2007, 17, 5897-5901.
18. Kong, Y.; Grembecka, J.; Edler, M. C.; Hamel, E.; Mooberry, S. L.; Sabat, M.; Rieger, J.; Brown, M. L. Structure-based discovery of a boronic acid bioisostere of combretastatin A-4. Chem. Biol. 2005, 12, 1007-1014.
19. Ducki, S.; Forrest, R.; Hadfield, J. A.; Kendall, A.; Lawrence, N. J.; McGown, A. T.; Rennison, D. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. 1998, 8, 1051-1056.
20. Ali, O. M.; Amer, H. H.; Abdel-Rahman, A. A.-H. Synthesis and antiviral evaluation of sugar uracil-1-ylmethylhydrazones and their oxadiazoline derivatives. Synthesis 2007, 18, 2823-2828.
21. (a) Song, Q.-B.; Zhang, J.; Tiekink, E. R. T. 2-[3-Acetyl-5-(3,6- dichloropyridin-2-yl)-2,3-dihydro-1,3,4-oxadiazol-2-yl]phenyl acetate. Acta Crystallogr. 2006, E62, o4115-o4117.
22. (b) Qin, Q.; Xu, L. J.; Pan, L. F.; Chen, S. Q.; Song, Q. B. 2-[3-Acetyl-5-(2-chloro-3-pyridyl)-2-methyl-2,3-dihydro-1,3,4-oxadiazol-2-yl] -4-fluorophenyl acetate. Acta Crystallogr. 2009, E65, o1181.
23. Rae, J. M.; Creighton, C. J.; Meck, J. M.; Haddad, B. R.; Johnson, M. D.MDA-MB-435 cells are derived from M14 melanoma cells - A loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat. 2007, 104, 13-19.
24. Blagosklonny, M. V.; Darzynkiewicz, Z.; Halicka, H. D.; Pozarowski, P.; Demidenko, Z. N.; Barry, J. J.; Kamath, K. R.; Herrmann, R. A. Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells. Cell Cycle 2004, 3, 1050-1056.
25. Rao, P. N.; Cessac, J. W.; Tinley, T. L.; Mooberry, S. L. Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs. Steroids 2002, 67, 1079-1089.
26. Tripathi, A.; Fornabaio, M.; Kellogg, G. E.; Gupton, J. T.; Gewirtz, D. A.; Yeudall, W. A.; Vega, N. E.; Mooberry, S. L. Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity. Bioorg. Med. Chem. 2008, 16, 2235-2242.
27. Gupton, J. T.; Burham, B. S.; Krumpe, K.; Du, K.; Sikorski, J. A.; Warren, A. E.; Barnes, C. R.; Hall, I. H. Synthesis and cytotoxicity of 2,4-disubstituted and 2,3,4-trisubstituted brominated pyrroles in murine and human cultured tumor cells. Arch. Pharm. (Weinheim) 2000, 333, 3-9.
28. Tinley, T. L.; Leal, R. M.; Randall-Hlubek, D. A.; Cessac, J. W.; Wilkens, L. R.; Rao, P. N.; Mooberry, S. L. Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res. 2003, 63, 1538-1549.
29. Mooberry, S. L.; Weiderhold, K. N.; Dakshanamurthy, S.; Hamel, E.; Banner, E. J.; Kharlamova, A.; Hempel, J.; Gupton, J. T.; Brown, M. L. Identification and characterization of a new tubulin-binding tetra-substituted brominated pyrrole. Mol. Pharmacol. 2007, 72, 132-140.
30. Weiderhold, K. N.; Randall-Hlubek, D. A.; Polin, L. A.; Hamel, E.; Mooberry, S. L. CB694, a novel antimitotic with antitumor activities. Int. J. Cancer 2006, 118, 1032-1040.
31. Leonard, G. D.; Fojo, T.; Bates, S. E. The role of ABC transporters in clinical practice. Oncologist 2003, 8, 411-424.
32. Seve, P.; Dumontet, C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 2008, 9, 168-175.
33. Risinger, A. L.; Jackson, E. M.; Polin, L. A.; Helms, G. L.; LeBoeuf, D. A.; Joe, P. A.; Hopper-Borge, E.; Luduena, R. F.; Kruh, G. D.; Mooberry, S. L. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res. 2008, 68, 8881-8888.
34. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
35. Tinley, T. L.; Randall-Hlubek, D. A.; Leal, R. M.; Jackson, E. M.; Cessac, J. W.; Quada, J. C., Jr.; Hemscheidt, T. K.; Mooberry, S. L. Taccalonolides E and A: Plant-derived steroids with microtubulestabilizing activity. Cancer Res. 2003, 63, 3211-3220.